- Home
- EDF vs GLSI Comparison
EDF vs GLSI Comparison
Compare EDF & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- GLSI
- Stock Information
- Founded
- EDF 2010
- GLSI 2006
- Country
- EDF United States
- GLSI United States
- Employees
- EDF N/A
- GLSI N/A
- Industry
- EDF Investment Managers
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- EDF Finance
- GLSI Health Care
- Exchange
- EDF Nasdaq
- GLSI Nasdaq
- Market Cap
- EDF 148.8M
- GLSI 133.4M
- IPO Year
- EDF N/A
- GLSI 2020
- Fundamental
- Price
- EDF $4.97
- GLSI $8.90
- Analyst Decision
- EDF
- GLSI Strong Buy
- Analyst Count
- EDF 0
- GLSI 1
- Target Price
- EDF N/A
- GLSI $39.00
- AVG Volume (30 Days)
- EDF 160.6K
- GLSI 33.7K
- Earning Date
- EDF 01-01-0001
- GLSI 08-13-2025
- Dividend Yield
- EDF 13.14%
- GLSI N/A
- EPS Growth
- EDF N/A
- GLSI N/A
- EPS
- EDF N/A
- GLSI N/A
- Revenue
- EDF N/A
- GLSI N/A
- Revenue This Year
- EDF N/A
- GLSI N/A
- Revenue Next Year
- EDF N/A
- GLSI N/A
- P/E Ratio
- EDF N/A
- GLSI N/A
- Revenue Growth
- EDF N/A
- GLSI N/A
- 52 Week Low
- EDF $3.51
- GLSI $8.06
- 52 Week High
- EDF $5.50
- GLSI $18.15
- Technical
- Relative Strength Index (RSI)
- EDF 50.98
- GLSI 35.87
- Support Level
- EDF $4.96
- GLSI $9.40
- Resistance Level
- EDF $5.05
- GLSI $9.92
- Average True Range (ATR)
- EDF 0.07
- GLSI 0.29
- MACD
- EDF -0.01
- GLSI -0.07
- Stochastic Oscillator
- EDF 33.00
- GLSI 0.00
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.